Stifel reiterates Alumis stock Buy rating after psoriasis data By Investing.com

Phase 3 data for envudeucitinib showed PASI100 rates of 29%/41% (week 16/24) and 28%/40%, presented from two ONWARD trials involving >1,700 patients, validating the TYK2 IC90 thesis. Stifel reiterated a Buy with a $44 PT and highlighted potential differentiated labeling; Raymond James initiated Strong Buy with a $46 PT, while H.C. Wainwright cut its PT to $25 from $40 citing increased competition. ALMS has surged ~340% over the past year, trades at $24.80 with a $3.15B market cap, and InvestingPro flags it as appearing overvalued; Stifel notes 3Q26 SLE data as a key next catalyst.

Analysis

The clinical readout places ALMS at an inflection where mechanistic plausibility (oral TYK2 hitting deep IL-23 downstreams) can compress the incumbent biologics’ pricing power — payers will favor lower-cost oral alternatives if real-world safety matches trial safety, which could accelerate formulary switches and constrain ASPs for monoclonals. Because small-molecule manufacturing has far lower per-unit COGS and faster scale-up versus biologics, a material market share shift would meaningfully expand gross margins for a successful oral player and allow aggressive volume-based contracting that incumbents will struggle to match.

Competition among next-gen TYK2/JAK-like agents creates a binary market structure: a few entrants that can demonstrate clear safety/label differentiation win disproportionate share while the rest face rapid value destruction. That dynamic increases the probability of consolidation — large pharm buyers will pay premiums for clean safety profiles with differentiated labels to secure an oral alternative to high-priced injectables, while near-term commercial headwinds will compress the exit multiples for second-tier players.

Near-term volatility will be dominated by data sequencing and labeling-language interpretation from regulators and payers rather than headline efficacy numbers alone. A marginal safety nuance in post-market surveillance or label wording (black-box, boxed warnings, age-limited indications) would materially reduce uptake and reprice expectations; conversely, an advantageous label with no class safety constraints would drive rapid re-rating and invite aggressive partnership bids. Time horizons: trading windows open immediately around subsequent readouts/label milestones (days–weeks), commercialization and formulary dynamics play out over 12–36 months, structural peak-share and M&A outcomes realize over multiple years.

Key Decisions for Investors

• Directional asymmetric long (ALMS): buy 9–15 month call spreads to cap premium (buy nearer-term ATM call, sell 1.5x strike). Rationale: captures upside if labeling/payer outcomes are favorable while limiting downside to the paid premium. Target risk/reward: 1x downside (premium) vs potential 3–5x upside per spread if commercial adoption accelerates within 12 months.
• Event-protected equity long (ALMS): purchase shares with 6–9 month puts as downside insurance (protects against binary negative regulatory/payer outcomes). Rationale: long equity exposure to M&A/label upside while limiting tail risk; cost equals put premium. Aim to keep hedged drawdown to <30% over the hedge period.
• Pair/relative-value: long ALMS call spread vs short a broad oral non-biologic peer basket (equal-weighted). Rationale: express conviction in ALMS’ differentiation while hedging class/regulatory risk. Use 12-month expiries and size such that delta-neutral exposure to class moves, capturing idiosyncratic upside if ALMS secures favorable label or partner.
• Volatility sell/hedge around readouts: sell short-dated implied volatility (e.g., 30–60 day iron condors) ahead of non-binary liquidity windows, but hedge with long-dated protection (LEAP puts) to avoid gap risk. Rationale: IV tends to overreact pre/post data; collect premium while limiting catastrophic exposure. Keep net max loss per structure <3–4% of trade book.